RXST - RxSight, Inc. Stock Price, Fair Value and News

$34.62+0.96 (+2.85%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

RXST Price Action

Last 7 days

-9.8%

Last 30 days

-24.9%

Last 90 days

-36.5%

Trailing 12 Months

-13.2%

RXST RSI Chart

RXST Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-45.46

Price/Sales (Trailing)

10.88

EV/EBITDA

-51.94

Price/Free Cashflow

-51.35

RXST Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RXST Fundamentals

RXST Revenue

Revenue (TTM)

128.3M

Rev. Growth (Yr)

59.08%

Rev. Growth (Qtr)

1.22%

RXST Earnings

Earnings (TTM)

-30.7M

Earnings Growth (Yr)

48.95%

Earnings Growth (Qtr)

-4.26%

RXST Profitability

EBT Margin

-23.91%

Return on Equity

-11.07%

Return on Assets

-9.89%

Free Cashflow Yield

-1.95%

RXST Investor Care

Shares Dilution (1Y)

12.39%

Diluted EPS (TTM)

-0.81

RXST Alerts

1 major insider buys and 2 major insider sales recently.
Big jump in Revenue (Y/Y)
Big jump in Earnings (Y/Y)
Losses in recent quarter

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	101.1M	115.2M	128.3M	0
2023	57.6M	67.0M	76.6M	89.1M
2022	28.1M	34.5M	41.3M	49.0M
2021	16.7M	18.6M	20.6M	22.6M
2020	0	0	0	14.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About RxSight, Inc.

RxSight, Inc., an ophthalmic medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

CEO	Dr. Ronald M. Kurtz M.D.
WEBSITE	rxsight.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	292

RxSight, Inc. Frequently Asked Questions

What is the ticker symbol for RxSight, Inc.? What does RXST stand for in stocks?

RXST is the stock ticker symbol of RxSight, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of RxSight, Inc. (RXST)?

As of Fri Dec 20 2024, market cap of RxSight, Inc. is 1.36 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RXST stock?

You can check RXST's fair value in chart for subscribers.

Is RxSight, Inc. a good stock to buy?

The fair value guage provides a quick view whether RXST is over valued or under valued. Whether RxSight, Inc. is cheap or expensive depends on the assumptions which impact RxSight, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RXST.

What is RxSight, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, RXST's PE ratio (Price to Earnings) is -44.2 and Price to Sales (PS) ratio is 10.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RXST PE ratio will change depending on the future growth rate expectations of investors.